Meeting
2023 ASCO Annual Meeting
SI-B001 plus chemotherapy in patients with locally advanced or metastatic EGFR/ALK wild-type non-small cell lung cancer: A phase II, multicenter, open-label study.
Authors
Yuanyuan Zhao
Department of Medical Oncology, Sun Yat-sen University Cancer Center & State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
Yuanyuan Zhao , Li Zhang , Wenfeng Fang , Yunpeng Yang , Yan Huang , Wen Zou , Zhaoxiang Wang , Muran Ding , Yujia Peng , Sa Xiao , Hongwei Wang , Hai Zhu , Martin Sebastian Olivo , Yi Zhu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Biologic Correlates
Clinical Trial Registration Number
05020457
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9025)
DOI
10.1200/JCO.2023.41.16_suppl.9025
Abstract #
9025
Poster Bd #
1
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
PIONEER: A multicenter, open-label, randomized phase II trial of second-line apatinib plus chemotherapy versus chemotherapy alone in gastric and gastroesophageal junction adenocarcinoma (GA/GEA) refractory to or intolerant of prior anti-PD-1 therapy.
First Author: Dandan Yu
Poster
2019 ASCO Annual Meeting
SGNTV-001: Open label phase 2 study of tisotumab vedotin for locally advanced or metastatic disease in solid tumors.
First Author: David S. Hong
Poster
2023 ASCO Annual Meeting
ALMB-0168, a novel Cx43 hemichannel agonist monoclonal antibody, for metastatic or unresectable osteosarcoma after standard chemotherapy: A multicenter, open-label, single-arm, phase 1 study.
First Author: Jingnan Shen
Poster
2023 ASCO Annual Meeting
The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study.
First Author: Jianqing Zhu